Tonix Pharmaceuticals stock halted ahead of FDA approval news
DUBLIN - Glanbia plc (ISE:GL9), the nutrition company, announced Wednesday the appointment of Paul Duffy as Chair Designate, effective immediately. Duffy will succeed current Chair Donard Gaynor on January 1, 2026, following Gaynor’s retirement on December 31, 2025.
The appointment follows what the company described as a comprehensive succession process led by Senior Independent (LON:IOG) Director Roisin Brennan.
Duffy, who has served as an Independent Non-Executive Director at Glanbia since March 2021, currently chairs the company’s Audit Committee and serves on its Nomination & Governance and Remuneration Committees.
Prior to joining Glanbia’s board, Duffy held several senior leadership positions during a 25-year career at Pernod Ricard (EPA:PERP), including Chairman and CEO roles at Pernod Ricard North America, Pernod Ricard UK, The Absolut Company, and Irish Distillers. He also served on Pernod Ricard’s global management executive committee.
"It is a privilege to be appointed Chair of Glanbia plc," Duffy said in a statement. "I look forward to working with the Glanbia Board and leadership team on the focused delivery of strategy and value creation for our stakeholders."
Gaynor, who will step down after 12 years with the company, was Glanbia’s first independent Chair. He expressed gratitude to CEO Siobhán Talbot, Hugh McGuire, board colleagues and shareholders for their support during his tenure.
Duffy is also currently a Non-Executive Director of Hostelworld Group plc and W.A. Baxter (NYSE:BAX) & Sons, and previously served as Chairman of Irish Children’s Museum CLG.
The announcement was made in a press release issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.